目的 系统评价沙格列汀治疗2型糖尿病的经济学特性。方法 系统检索PubMed、Embase、Cochrane Library和CNKI、Wanfang、CBM等数据库,根据标准筛选文献,并使用CHEERS量表进行质量评价,对研究结果进行系统性分析。结果 共纳入8项研究,均为成本-效果研究,其中1项来自中国。患者人群均为单药治疗血糖控制不佳。沙格列汀与磺脲类药物(格列吡嗪和格列美脲)、噻唑烷二酮类药物(罗格列酮和吡格列酮)相比,联合二甲双胍时具有成本效果优势;与NPH胰岛素相比,联合二甲双胍或磺脲类药物时具有成本效果优势。结论 沙格列汀治疗单药治疗血糖控制不佳的2型糖尿病具有良好的经济学优势。
Abstract
OBJECTIVE To systematically evaluate the economics of saxagliptin for treatment of type 2 diabetes mellitus. METHODS PubMed, Embase, Cochrane Library, NHS EED, CNKI, Wanfang and CBM were systematically searched. Literatures were screened according to pre-defined inclusion criteria. The quality of included studies were evaluated by CHEERS statement and the economic RESULTS were systematically analyzed. RESULTS Eight cost-effectiveness analyses were included, one of which was conducted in China. Patients among the studies all had blood glucose non-adeguately controlled by monotherapy. When added on to metformin, saxagliptin was cost-effective compared with sulfonylureas (glipizide and glimepiride) and thiazolidinediones (pioglitazone and rosiglitazone). When added on to metformin or sulfonylureas, saxagliptin was cost-effective compared with NPH insulin. CONCLUSION Saxagliptin represents a cost-effective option in treatment of type 2 diabetes mellitus patients with non-adequately controlled blood glucose after monotherapy.
关键词
2型糖尿病 /
系统评价 /
沙格列汀 /
药物经济学
{{custom_keyword}} /
Key words
type 2 diabetes mellitus /
systematic review /
saxagliptin /
pharmacoeconomics
{{custom_keyword}} /
中图分类号：
R969
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] KAHN S E, COOPER M E, DEL PRATO S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future [J]. Lancet, 2014, 383(9922): 1068-1083.
[2] CAMPBELL R K, COBBLE M E, REID T S, et al. Pathophysiology of type 2 diabetes mellitus: potential role of incretin-based therapies [J]. J Fam Pract, 2010, 59(9 suppl 1): S5-S9.
[3] BERGENHEIM K, WILLIAMS S A, BERGESON J G, et al. US cost-effectiveness of saxagliptin in type 2 diabetes mellitus [J]. Am J Pharm Benefits, 2012, 4(1):20-28.
[4] CRISTIANI M, CITARELLA A, BELISARI A, et al. Valutazione economica dell′impiego di saxagliptin nel trattamento del diabete di tipo 2 in Italia [J]. Farmeconomiae Percorsi Terapeutici,2010, 11(2):103-115.
[5] ELGART J F, CAPORALE J E, GONZALEZ L, et al. Treatment of type 2 diabetes with saxagliptin: a pharmacoeconomic evaluation in Argentina [J]. Health Econ Rev, 2013, 3(1):11.
[6] ERHARDT W, BERGENHEIM K, DUPRAT-LOMON I, et al. Cost effectiveness of saxagliptin and metformin versus sulfonylurea and metformin in the treatment of type 2 diabetes mellitus in Germany: a Cardiff diabetes model analysis [J]. Clin Drug Investig, 2012, 32(3):189-202.
[7] GRANSTRM O, BERGENHEIM K, MCEWAN P, et al. Cost-effectiveness of saxagliptin (Onglyza) in type 2 diabetes in Sweden [J]. Prim Care Diabetes, 2012, 6(2):127-136.
[8] GRZESZCZAK W, CZUPRYNIAK L, KOLASA K, et al. The cost-effectiveness of saxagliptin versus NPH insulin when used in combination with other oral antidiabetes agents in the treatment of type 2 diabetes mellitus in Poland [J]. Diabetes Technol Ther, 2012, 14(1):65-73.
[9] GU S, DENG J, SHI L, et al. Cost-effectiveness of saxagliptin vs glimepiride as a second-line therapy added to metformin in type 2 diabetes in China [J]. J Med Econ, 2015, 18(10):808-820.
[10] NITA M E, ELIASCHEWITZ F G, RIBEIRO E, et al. Cost-effectiveness and budget impact of saxagliptine as additional therapy to metformin for the treatment of diabetes mellitus type 2 in the Brazilian private health system [J]. Rev Assoc Med Bras, 2012, 58(3):294-301.
[11] CHACRA A R, TAN G H, APANOVITCH A, et al. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial [J]. Int J Clin Pract, 2009, 63(9):1395-1406.
[12] GOKE B, GALLWITZ B, ERIKSSON J, et al. Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial [J]. Int J Clin Pract, 2010, 64(12):1619-1631.
[13] DEFRONZO R A, HISSA M N, GARBER A J, et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone [J]. Diabetes Care, 2009, 32(9):1649-1655.
[14] MONAMI M, MARCHIONNI N, MANNUCCI E. Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a Meta-analysis [J]. Diabetes Res Clin Pract, 2008, 81(2):184-189.
[15] PRADHAN A D, EVERETT B M, COOK N R, et al. Effects of initiating insulin and metformin on glycemic control and inflammatory biomarkers among patients with type 2 diabetes: the LANCET randomized trial [J]. JAMA, 2009, 302(11):1186-1194.
[16] PHUNG O J, SCHOLLE J M, TALWAR M, et al. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes [J]. JAMA, 2010, 303(14):1410-1418.
[17] ZHU F, SONG X. Therapeutic effects of dipeptidyl peptidase-4 inhibitor saxagliptin on patients with type 2 diabetes and its influences on β-cell function [J]. Chin J Diabetes, 2014, 22(6):494-496.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
PDF(828 KB)
